L
2.75
-1.15 (-29.49%)
| Previous Close | 3.90 |
| Open | 2.57 |
| Volume | 382,371 |
| Avg. Volume (3M) | 38,886 |
| Market Cap | 23,085,976 |
| Price / Book | 0.660 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -2.51 |
| Total Debt/Equity (MRQ) | 0.59% |
| Current Ratio (MRQ) | 9.42 |
| Operating Cash Flow (TTM) | -19.96 M |
| Levered Free Cash Flow (TTM) | -13.25 M |
| Return on Assets (TTM) | -28.72% |
| Return on Equity (TTM) | -44.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Lisata Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
0.0
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.12% |
| % Held by Institutions | 9.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cook Wealth, Llc | 30 Sep 2024 | 12,175 |
| Founders Capital Management | 31 Dec 2024 | 2,000 |
| 52 Weeks Range | ||
| Median | 15.00 (445.46%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2024 | 15.00 (445.45%) | Buy | 2.62 |
| 21 Nov 2024 | 15.00 (445.45%) | Buy | 2.84 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2025 | Announcement | Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |